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postmenopausal women attending a clinic in Western New York, to undergo mammo-
graphic assessment. Eligible participants included women without cancer, no recent 
use of hormone-replacement therapy, and no history of breast augmentation or breast 
reduction surgery. A self-administered questionnaire was used to obtain information 
on demographics, anthropometry, and breast cancer risk factors. Percent density (PD) 
was measured using computer-assisted assessment of mammographic films. General 
linear models were used to test for differences in PD by smoking variables while 
adjusting for selected covariates (age, body mass index, age at first live birth, age at 
menopause, use of hormone therapy, level of education, and family history of breast 
cancer). Results: Study participants (n= 229) included 125 never-smokers, 87 former 
smokers, and 17 current smokers. Current smokers had a lower mean percent density 
(SE) compared to non-current smokers and former smokers (29.6 (5.1) vs. 34.8 (3.9) 
and 37.5 (4.1) p= 0.09). Among ever smokers, age at smoking initiation was inversely 
associated with percent density (P= 0.002). No significant associations were observed 
for the other smoking variables. ConClusions: Younger age at smoking initiation is 
associated with higher PD while current smoking is associated with lower PD. These 
findings suggest that smoking may have differential effects on risk of postmenopau-
sal breast cancer depending on the timing of exposure.
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objeCtives: Surgery is a standard modality in the modern management of solid 
tumors. Unfortunately, some patients will experience unplanned readmissions and 
ED visits following their operation. Emerging trends in health reform have intro-
duced new financial detriments to hospital reencounters in addition to the negative 
impact on quality of care. Our objective was to develop an electronic approach to 
assessing unplanned hospital reencounters following common cancer operations 
in order to guide decision-making aimed improving value in our patient popula-
tion. Methods: The target population for this study was adult cancer patients 
undergoing mastectomy and colectomy operations for cancer. Data were abstracted 
using an Electronic Data Warehouse (EDW) to determine 30-day emergency depart-
ment visits and hospital readmissions following the selected cancer operations. 
The secondary outcome measure was cost of care for patients returning to the 
hospital within 30-days. Results: Among 105 patients undergoing selected breast 
and colon cancer operations from January 1, 2012 to December 31, 2012 the hospital 
reencounter rate was 11.9%. Wound-related complications were responsible for 
73% of these hospital reencounters. Total costs (direct and indirect) for hospital 
reencounters were $210,722.76. ConClusions: Unplanned hospital readmissions 
and emergency department visits following cancer surgery largely result from post-
operative complications. These unplanned reencounters are a costly source of poor 
quality care. Patient-centered, disease-specific efforts to reduce unplanned hospital 
reencounters have the potential to significantly increase quality while decreas-
ing costs. Using data for decision-making in quality improvement is important for 
achieving value in patient care.
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objeCtives: Bevacizumab is a recombinant, humanized monoclonal antibody that 
hinders the proliferation of new blood vessels in malignant cells. It plays an impor-
tant role in the management of colorectal cancer; however, there is concern about its 
association with the development of thrombosis. The purpose of current study was 
to address the overall risk of thrombotic events in colorectal cancer patients treated 
with Bevacizumab-based chemotherapy as well as the risk of both arterial and 
venous thrombotic events separately. Methods: PUBMED/MEDLINE database was 
searched to find relevant clinical trials that published in English language between 
the periods January 1st, 2003 and December 31st 2013. Only randomized control tri-
als (RCTs) that compared non-Bevacizumab to Bevacizumab-based chemotherapy 
regimen for the treatment of colorectal cancer and reported thrombotic events 
were included. The relative risk (RR) with 95% confidence intervals of thrombotic 
events was calculated. Because between-study heterogeneity was insignificant, 
the fixed effect model was used to calculate the estimated effect sizes. Results: 
There were a total of 22 randomized clinical trials that have met our search criteria 
with a total of 12,852 patients used for safety analysis calculations. Based on our 
findings, there is a significant risk of overall thrombotic events in Bevacizumab vs 
control treated group RR = 1.315 (95% CI 1.165-1.483, P = < .0001). In terms of venous 
thrombosis, there is a significant risk in Bevacizumab treated patients with a RR 
= 1.256 (95% CI 1.097-1.43, P = 0.0019) compared to control. Finally, a higher risk of 
arterial thrombosis in patients used Bevacizumab vs control treated groups RR = 
1.635 (95% CI 1.1802.264, P = 0.0065). Sensitivity analyses showed no significant dif-
ferences. ConClusions: Bevacizumab-based chemotherapy is significantly asso-
ciated with the development of thrombotic events either as venous or as arterial 
thrombosis. Health care providers are encouraged to consider thrombosis prophy-
laxis regimen and periodically monitoring their patients.
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objeCtives: To determine if cardiovascular (CV) drugs are associated with an 
increased risk of colon cancer (CC) & if the risk for any individual agent differs from 
inhibitors or to ARBs experienced a significantly decreased all-cause mortality risk 
as compared to those who were not (HR= 0.90, 95% CI: 0.85 – 0.95 and HR= 0.92, 95% 
CI: 0.86 – 0.98, respectively). ConClusions: Our population-based study showed 
that the use of ACE inhibitors and ARBs was associated with reduced overall mortal-
ity in patients with pancreatic cancer. Although modest, such benefits may be of 
great clinical importance because of the low overall survival rate seen in patients 
with pancreatic cancer and the relative safety of ACE inhibitors and ARBs. These 
relationships should be further examined in other populations using similar mod-
eling techniques.
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objeCtives: SREs are common in men with mPC and some individuals experi-
ence multiple SREs. We estimated the burden and timing of SREs in elderly men 
diagnosed with mPC. Methods: We analyzed elderly men diagnosed with mPC 
between 2000-2009 in the SEER-Medicare datasets and followed through 12/31/2010 
or until lost to follow-up. Post-diagnosis SREs were identified using claims that 
indicated spinal cord compression (SCC), pathologic fracture (PF), surgery to bone 
(SB), or radiation (RAD, potentially suggestive of bone palliative radiation). Results: 
Among 8,997 mPC men with a median follow up of 18 months, 4,176 (47.7%) expe-
rienced at least one SRE. The median (mean) time from mPC diagnosis to first SRE 
was 154 (335) days. The median times from mPC diagnosis to first RAD, PF, SCC, or 
SB were 204, 96, 44, or 85 days, respectively. Of the 4,176 men who had at least one 
SRE, 2,619 (62.7%) had a subsequent SRE and 1,442 (35%) had a subsequent SRE of 
a different type. The median (mean) time from first SRE to any second SRE was 23 
(108) days, while it was 21 (177) days from first SRE to second SRE of a different type. 
Subsequent SRE patterns varied considerably depending on the first SRE type. The 
majority of patients who experienced a PF or SCC first quickly had SB within 2 days 
or RAD within a month. ConClusions: The median time from first SRE to second 
SRE was considerably shorter than the median time from mPC diagnosis to first SRE, 
suggesting that once patients have had an SRE, it is quicker to develop subsequent 
SREs. Individuals who had a PF or SCC as a first SRE received RAD or SB within one 
month. These findings provide additional data to guide monitoring and prevention 
of SREs in the elderly mPC population.
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objeCtives: Advanced (stage IIIB/C and IV) melanoma is an aggressive, deadly 
disease and has a high detrimental impact on patients and society, primarily due 
to premature death. Understanding the burden of advanced melanoma is therefore 
important for health policy and allocating appropriate health care resources to 
treatment. There is limited data available specifically related to burden of advanced 
melanoma on patients. The aim of this study was to estimate years of life lost in 
patients with advanced melanoma in 12 countries. Methods: Population growth 
and life expectancy were estimated from OECD data and country-specific life tables, 
respectively. Incidence and mortality data for advanced melanoma were collected 
from local cancer registries and GLOBOCAN 2008. Population growth and incidence 
rates by stage of disease were used to estimate the growth in the size of the mela-
noma patient population and new cases of advanced melanoma in 2014, respec-
tively. Melanoma-specific mortality rates were used to estimate the number of 
patients surviving from previous years, to calculate prevalence, mortality and age at 
death for patients with advanced melanoma. Age and sex-adjusted life tables were 
subsequently used to estimate years of life lost for these patients. Results: Years 
of life lost due to advanced melanoma per patient were as follows: Australia (men: 
19.9 years, women: 22.7 years); Brazil (16.3, 19.8); Canada (19.4, 22.3); France (18.8, 
23.1); Germany (18.3, 20.8); Italy (19.3, 22.7); Mexico (17.2, 19.0); the Netherlands (18.5, 
21.5); Spain (19.2, 23.1); Sweden (19.4, 22.0); UK (18.7, 21.2); US (17.9, 20.6). Country 
differences were primarily driven by melanoma mortality rates and disease-free 
life expectancy. ConClusions: This study estimated the years of life lost due to 
advanced melanoma in 12 countries and found variations across countries and vari-
ations between sexes; however, the burden of advanced melanoma is substantial 
in all of the countries.
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objeCtives: Tobacco contains numerous carcinogens, including several known to 
cause mammary tumors in animal models. Our study aimed to investigate whether 
mammographic density (MD), a recognized risk factor associated with breast cancer, 
is influenced by smoking history. Methods: This was a cross-sectional study of 
